Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTX-030 monotherapy and combinations in advanced cancers
NCT03884556Phase 1Completed
- Sponsor
- Trishula Therapeutics
- Start
- Apr 2019
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of eztilimab in solid tumor and lymphoma (3 arms), sponsored by Trishula Therapeutics. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities and Objective Response Rate. Started Apr 2019; status: completed.
02
Drugs
eztilimab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03884556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884556.